Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative COX-2 inhibition for prevention of central sensitisation after breast cancer surgery
NL-OMON20830Recruiting
- Sponsor
- 03-06-2009 update: UMC St. Radboud and Bernhoven Hospital
- Start
- Oct 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of celecoxib and parecoxib in Persistent postsurgical pain (PPSP) and breast cancer (2 arms), sponsored by 03-06-2009 update: UMC St. Radboud and Bernhoven Hospital. Primary endpoint: Persistence and extent of central sensitisation at 1 month. Started Oct 2006; status: recruiting.
02
Drugs
celecoxibparecoxib
03
Conditions
Persistent postsurgical pain (PPSP)breast cancer
Beyond the preview
Go deeper on NL-OMON20830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20830.